Study of PF-07263689 in Participants With Selected Advanced Solid Tumors. A Phase 1, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Pharmacodynamics of PF-07263689, Either Alone or in Combination With an Anti-PD-1 Antibody, in Previously Treated Participants With Selected Locally Advanced or Metastatic Solid Tumors.